Rozibafusp alfa

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameRozibafusp alfa
Drug Alias NameAMG-570MEDI-0700
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody polypeptide conjugate (APC)
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitorsICOS ligand inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulatorICOS ligand
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A